Zhejiang Xianju Pharmaceutical (SHE:002332) said the 1ml:50mg specification for progesterone injection passed China's generic drug consistency evaluation.
The injection is indicated for menstrual disorders, luteal deficiency, threatened and habitual abortion, premenstrual tension syndrome, and assisted reproductive therapy, according to a Wednesday filing with the Shenzhen bourse.
The pharmaceutical company already holds approvals for 1ml:10mg and 1ml:20mg specifications.
Shares of Zhejiang Xianju Pharmaceutical were down 2% Wednesday.